Sign-up for Gynecologic Oncology Group (GOG) Phase 2 Study of Advaxis's Lm-LLO Immunotherapy, ADXS-HPV, for the Treatment of Persistent or Recurrent Cervical Cancer Achieves Safety and Efficacy Criteria investment picks
Pfizer Inc. (NYSE:PFE) today announced the publication of the detailed
results from PALOMA-1, a randomized Phase 2 study of palbociclib in
combination with letrozole versus letrozole alone, in The Lancet
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.